Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation

Transfusion

Volumn 55, Issue 8, 2015, Pages 1993-2000

  Gattillo, Salvatore ^a   Marktel, Sarah ^a   Rizzo, Lorenzo ^a   Malato, Simona ^a   Malabarba, Lucia ^a   Coppola, Milena ^a   Assanelli, Andrea ^a   Milani, Raffaella ^a   De Freitas, Tiago ^a   Corti, Consuelo ^a   Bellio, Laura ^a   Ciceri, Fabio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LENOGRASTIM; LEVOTHYROXINE; PLERIXAFOR; VENLAFAXINE; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND; RECOMBINANT PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE PAIN; CANCER THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG CONTRAINDICATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FOLLOW UP; GRAFT FAILURE; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HYPOTHYROIDISM; INFLUENZA A (H1N1); KIDNEY CARCINOMA; LEUKAPHERESIS; MALE; MIDDLE AGED; PSYCHOPHARMACOTHERAPY; STEM CELL MOBILIZATION; VIRUS PNEUMONIA; VOMITING; ADVERSE EFFECTS; ALLOGRAFT; BLOOD; BLOOD CELL COUNT; CARCINOMA, RENAL CELL; CASE REPORT; CFU COUNTING; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; DRUG POTENTIATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; LIVING DONOR; PAIN; PARENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SIBLING; TREATMENT OUTCOME;

ADULT; AGED; ALLOGRAFTS; ANTIGENS, CD34; BLOOD CELL COUNT; CARCINOMA, RENAL CELL; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY NEOPLASMS; LEUKAPHERESIS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; PAIN; PARENTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINANT PROTEINS; SIBLINGS; TREATMENT OUTCOME;

EID: 84938980089     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13059     Document Type: Article

References (28)

1. Tricot G, Jagannath S, Vesole D, et al., Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
2. Martelli MF, Reisner Y,. Haploidentical 'megadose' CD34+ cell transplants for patients with acute leukemia. Leukemia 2002; 16: 404-5.
3. Ings SJ, Balsa C, Leverett D, et al., Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-25.
4. Wang TF, Wen SH, Chen RL, et al., Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008; 14: 1305-11.
5. Anderlini P, Przepiorka D, Seong C, et al., Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-12.
6. Broxmeyer HE, Orschell CM, Clapp DW, et al., Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-18.
7. Hübel K, Liles WC, Broxmeyer HE, et al., Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165-72.
8. Liles WC, Broxmeyer HE, Rodger E, et al., Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.
9. Lemery SJ, Hsieh MM, Smith A, et al., A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol 2011; 153: 66-75.
10. Hauge AW, Haastrup EK, Sengelov H, et al., Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014; 54: 1055-8.
11. Milone G, Martino M, Spadaro A, et al., Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014; 164: 113-23.
12. Neumann T, Krüer WH, Busemann C, et al,. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant 2011; 46: 762-3.
13. Schriber J, Fauble V, Sproat LO, et al., Plerixafor 'just in time' for stem cell mobilization in a normal donor. Bone Marrow Transplant 2011; 46: 1026-7.
14. Glucksberg H, Storb R, Fefer A, et al., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
15. Przepiorka D, Weisdorf D, Martin P, et al., 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8.
16. Filipovich AH, Weisdorf D, Pavletic S, et al., National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-56.
17. Shulman HM, Sullivan KM, Weiden PL, et al., Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-17.
18. Rutella S, Filippini P, Bertaina V, et al., Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts. J Transl Med. 2014; 12: 240.
19. Anderlini P, Rizzo JD, Nugent ML, et al., Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689-92.
20. Stroncek D, Shawker T, Follmann D, et al., GCSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609-13.
21. Balaguer H, Galmes A, Ventayol G, et al., Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1.
22. Becker PS, Wagle M, Matous S, et al., Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-9.
23. Dincer AP, Gottschall J, Margolis DA,. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761-3.
24. Falzetti F, Aversa F, Minelli O, et al., Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
25. Hernández JM, Castilla C, Gutiérrez NC, et al., Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088-91.
26. Nagler A, Korenstein-Ilan A, Amiel A, et al., Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-30.
27. Lundqvist A, Smith AL, Takahashi Y, et al., Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol 2013; 191: 6241-9.
28. Peccatori J, Forcina A, Clerici D, et al., Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015; 29: 396-405.